NCT06789172
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06789172
Title A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors (INVOKE)
Acronym INVOKE
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Epkin
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA | GBR | AUS

Facility Status City State Zip Country Details
Precision NextGen Oncology and Research Center RECRUITING Beverly Hills California 90212 United States Details
Sarcoma Oncology Center RECRUITING Santa Monica California 90403 United States Details
MD Anderson Cancer Center RECRUITING Houston Texas 77030 United States Details
Chris O'Brien Lifehouse RECRUITING Sydney New South Wales Australia Details
Linear Clinical Research RECRUITING Perth Western Australia 6009 Australia Details
The Beatson RECRUITING Glasgow United Kingdom Details
Leicester Royal Infirmary RECRUITING Leicester LE1 5WW United Kingdom Details
University College London Hospital RECRUITING London United Kingdom Details
The Christie RECRUITING Manchester United Kingdom Details
Churchill Hospital RECRUITING Oxford United Kingdom Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field